- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.10. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.09. | Athira Pharma announces 10-for-1 reverse stock split | 11 | Seeking Alpha | ||
| 11.09. | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | 209 | GlobeNewswire (Europe) | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| 11.09. | Athira Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 07.08. | Athira Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Athira Pharma, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.05. | Athira Pharma, Inc.: Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit | 2 | GlobeNewswire (USA) | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 09.05. | Athira Pharma GAAP EPS of -$0.23 beats by $0.01 | 2 | Seeking Alpha | ||
| 09.05. | Athira Pharma, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 09.05. | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | 511 | GlobeNewswire (Europe) | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen | |
| 09.05. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 586 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11.24 | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 439 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | -2,67 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| INFLARX | 1,251 | -0,95 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,185 | +0,51 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| ABIVAX | 90,20 | +0,67 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| GERON | 1,077 | -1,06 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,390 | +2,57 % | FDA-Sonderstatus für Krebstherapie beflügelt Cellectar-Aktie | ||
| GALAPAGOS NV | 27,180 | -1,38 % | Galapagos NV: Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development | New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board
Mechelen, Belgium; October 30, 2025, 21:01 CET - Galapagos NV (Euronext & NASDAQ:... ► Artikel lesen | |
| VIDAC PHARMA | 0,530 | +3,52 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,992 | -1,63 % | Cardiff Oncology: Neue Impulse voraus? | Mit der Aktie von Cardiff Oncology haben Mitglieder von sharedealsPlus in der Vergangenheit mehrfach hervorragend verdient. Zuletzt konnten im Rahmen eines Daten-Run-up-Szenarios über 30% Kursgewinn... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,479 | +1,86 % | Coherus Oncology, Inc.: Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| SENSEI BIOTHERAPEUTICS | 9,570 | 0,00 % | Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value | BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| CYTOKINETICS | 55,00 | -0,90 % | Cytokinetics, Incorporated: Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 |
Das Unternehmen ATHIRA PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,145 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.